| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-01-07 | Addex Therapeutics (Switzerland) National Institute on Alcohol Abuse and Alcoholism (NIAAA) (USA) | ADX71441 | alcohol use disorder | collaboration |
CNS diseases | Collaboration agreement |
| 2015-01-07 | Ferrer (Spain) Cipher Pharmaceuticals (Canada) | ozenoxacin | impetigo | licensing |
Infectious diseases - Dermatological diseases | Licensing agreement |
| 2015-01-07 | Anthera Pharmaceuticals (USA - CA) | nomination |
Nomination | |||
| 2015-01-07 | Ultragenyx Pharmaceutical (USA - CA) Inserm Transfert (France) Institut du Cerveau et de la Moelle Epiniere (ICM) (France) | triheptanoin (UX007) | Huntington\'s disease | licensing |
Rare diseases - Genetic diseases - Neurodegenerative diseases | Licensing agreement |
| 2015-01-07 | Aveo Oncology (USA - MA) | nomination |
Cancer - Oncology | Nomination | ||
| 2015-01-07 | Transgene (France) | restructuring |
Cancer - Oncology | Restructuring | ||
| 2015-01-06 | Gilead Sciences (USA - CA) Phenex Pharmaceuticals (Germany) | Farnesoid X Receptor (FXR) program | liver diseases including NASH (non-alcoholic steatohepatitis) | product acquisition |
Hepatic diseases - Liver diseases - Metabolic diseases | Product acquisition |
| 2015-01-06 | Isis Pharmaceuticals (USA - CA) Akcea Therapeutics (USA - CA) | establishment of a new subsidiary in the US - nomination | Cardiovascular diseases - Rare diseases | Establishment of a new subsidiary in the US | ||
| 2015-01-06 | Cytos Biotechnology (Switzerland) OnCore Biopharma | virus like particle (VLP) platform | hepatitis B | licensing |
Infectious diseases | Licensing agreement |
| 2015-01-06 | Janssen Biotech, a J&J company (USA - NJ) Vectura (UK) | anti-inflammatory therapies | asthma, chronic obstructive pulmonary disease (COPD) | development licensing |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Licensing agreement |
| 2015-01-06 | Nestlé Health Sciences (Switzerland) Flagship Ventures (USA - MA) | Nutrition - Metabolic diseases | Collaboration agreement | |||
| 2015-01-06 | Immunomedics (USA - NJ) | nomination |
Autoimmune diseases – Cancer - Oncology | Nomination | ||
| 2015-01-05 | Amgen (USA - CA) Kite Pharma (USA - CA) | Chimeric Antigen Receptor (CAR) T cell immunotherapies | R&D licensing |
Cancer - Oncology | R&D agreement | |
| 2015-01-05 | Isis Pharmaceuticals (USA - CA) | nomination |
Nomination | |||
| 2015-01-05 | Boehringer Ingelheim (Germany) BioMed X (Germany) | novel therapeutic concepts | chronic obstructive pulmonary disease (COPD) | collaboration |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Collaboration agreement |
| 2015-01-05 | Catalyst Pharmaceutical Partners (USA - FL) | nomination |
Nomination | |||
| 2015-01-05 | Silence Therapeutics (UK) | nomination |
Nomination | |||
| 2015-01-05 | Audentes Therapeutics (USA - CA) | member of the board of directors | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2015-01-02 | Grifols (Spain) | new plant of the Grifols’ industrial complex in Los Angeles | validation of a production plant |
Validation of a production plant | ||
| 2014-12-30 | Ariad Pharmaceuticals (USA - MA) Angelini Pharma (Italy) | Iclusig® (ponatinib) | chronic myeloid leukemia (CML), Philadelphia -chromosome positive acute lymphoblastic leukemia (Ph+ ALL) | commercialisation |
Cancer - Oncology | Commercialisation agreement |
